Brief: Foghorn Therapeutics Provides Update On FHD-286 Phase I Study In Relapsed/Refractory AML/MD

Foghorn Therapeutics

23/08/2022 13:51

Aug 23 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS PROVIDES FURTHER UPDATE ON FHD-286
PHASE I
STUDY IN RELAPSED/REFRACTORY AML/MDS
    * FOGHORN THERAPEUTICS INC.- U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) HAS PLACED A FULL CLINICAL HOLD ON PHASE 1 DOSE ESCALATION
STUDY OF FHD-286
    * FOGHORN THERAPEUTICS INC.- PLANS TO REPORT DATA FROM MUM
STUDY
IN FIRST HALF OF 2023
    * FOGHORN THERAPEUTICS- HOLD IN STUDY DUE TO OBSERVATION OF
ADDITIONAL SUSPECTED CASES OF FATAL DIFFERENTIATION SYNDROME
BELIEVED TO BE RELATED TO FHD-286

Source text for Eikon:  ID:nGNX5fRN8Y 
Further company coverage:  FHTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))